Aligos Therapeutics Announces Reverse Stock Split: What It Means for Investors
In a recent press release, Aligos Therapeutics, a biopharmaceutical company focused on liver and viral diseases, announced a 1-for-25 reverse stock split of its common shares.This move will become effective on August 19, 2024, with the company’s stock trading on the Nasdaq Capital Market under the symbol ALGS on a split-adjusted basis.
Prior to the reverse stock split, Aligos had 43.496975 million shares outstanding with a current price of $0.493.Following the split, the total number of shares will be reduced significantly while the price per share will increase proportionally.
The impact of this reverse stock split on Aligos’ shares is two-fold.On one hand, the reduction in outstanding shares could potentially lead to increased stock value, making individual shares more valuable.On the other hand, some investors may see this move as a red flag, questioning why the company felt the need to execute a reverse stock split.
Overall, the long-term effects of this reverse stock split on Aligos Therapeutics’ shares remain to be seen.Investors will need to carefully monitor the company’s performance and market reactions in the coming months to gauge the true impact of this strategic decision.
Comments